The U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Nasdaq Composite. In this environment, identifying high growth tech stocks requires careful consideration of their potential to thrive amidst economic uncertainties, driven by innovation and strong market positioning.
Name
Revenue Growth
Earnings Growth
Growth Rating
Super Micro Computer
24.75%
38.20%
★★★★★★
Circle Internet Group
30.80%
60.64%
★★★★★★
Mereo BioPharma Group
51.11%
57.42%
★★★★★★
Ardelyx
21.16%
61.58%
★★★★★★
TG Therapeutics
26.38%
38.75%
★★★★★★
AVITA Medical
27.42%
61.04%
★★★★★★
Alnylam Pharmaceuticals
23.86%
59.49%
★★★★★★
Alkami Technology
20.53%
76.67%
★★★★★★
Ascendis Pharma
35.02%
59.89%
★★★★★★
Lumentum Holdings
23.14%
103.97%
★★★★★★
Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare and orphan diseases, with a market cap of $2.65 billion.
Operations: Mirum Pharmaceuticals generates revenue primarily from its pharmaceutical segment, amounting to $379.25 million. The company focuses on developing and commercializing therapies for rare and orphan diseases.
Despite recent setbacks, including being dropped from several Russell indexes, Mirum Pharmaceuticals (MIRM) showcases resilience with promising developments in its drug pipeline. The company’s revenue is expected to grow by 16.5% annually, outpacing the US market average of 8.8%. This growth is underpinned by innovative treatments like volixibat for cholestatic pruritus and LIVMARLI for pediatric liver diseases, both reflecting significant R&D commitment and potential market impact. Additionally, MIRM’s strategic hire of Doug Sheehy as Chief Legal Officer strengthens its leadership amidst these advancements. With earnings projected to surge by 63.29% annually and a transition to profitability within three years, Mirum’s focus on niche biomedical solutions could redefine treatment standards in its sector.
MIRM Revenue and Expenses Breakdown as at Jul 2025
Simply Wall St Growth Rating: ★★★★★☆
Story Continues
Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States with a market cap of approximately $1.45 billion.
Operations: The company generates revenue primarily through the development and commercialization of innovative therapies, with reported earnings of $273.53 million.
Travere Therapeutics has recently been added to multiple Russell Growth indexes, signaling a positive market outlook despite its current unprofitability. With a robust pipeline highlighted by FILSPARI for rare kidney diseases, the company is making significant strides in biotechnology. Impressively, Travere’s R&D commitment is evident as it presented groundbreaking data at international conferences, potentially setting new treatment paradigms in nephrology. Moreover, a recent $68.97 million shelf registration suggests strategic financial planning to support these innovations. As it navigates through regulatory landscapes with promising clinical results, Travere’s trajectory in high-growth sectors appears poised for impactful developments.
TVTX Revenue and Expenses Breakdown as at Jul 2025
Simply Wall St Growth Rating: ★★★★★☆
Overview: ImmunityBio, Inc. is a commercial-stage biotechnology company focused on developing next-generation therapies to enhance natural immune systems against cancers and infectious diseases, with a market cap of approximately $2.46 billion.
Operations: The company generates revenue primarily through its biotechnology segment, amounting to $31.22 million. As a commercial-stage entity, its focus is on advancing therapies that leverage the body’s immune system to combat cancer and infectious diseases.
ImmunityBio is making significant strides in the biotech industry with a focus on innovative cancer treatments. The company’s recent approval by the MHRA for ANKTIVA® in combination with BCG for bladder cancer treatment marks a pivotal advancement, highlighting its commitment to addressing unmet medical needs. Despite being currently unprofitable, ImmunityBio’s aggressive R&D spending and strategic partnerships, like the recent MOU with Saudi Arabia’s Ministry of Investment, underscore its potential to revolutionize cancer care. With revenue growth projected at 49.7% annually and earnings expected to surge by 67.1%, ImmunityBio is poised for substantial growth as it transitions towards profitability over the next three years.
IBRX Earnings and Revenue Growth as at Jul 2025
Reveal the 227 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here.
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MIRM TVTX and IBRX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
